Syntara on advancing first-in-class Myelofibrosis therapy with multiple pipeline opportunities
Welcome to the latest HotCopper Capital Compass, where we’ve this week spoken to Syntara Ltd (ASX:SNT) chief Gary Phillips for a high-level overview on the biotech company’s objectives in treating blood cancers and fibrosis, what underpins its value proposition, an...
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
ASX News